These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 25012568)

  • 41. Identification of novel, potent and selective inhibitors of Polo-like kinase 1.
    Chen S; Bartkovitz D; Cai J; Chen Y; Chen Z; Chu XJ; Le K; Le NT; Luk KC; Mischke S; Naderi-Oboodi G; Boylan JF; Nevins T; Qing W; Chen Y; Wovkulich PM
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1247-50. PubMed ID: 22172702
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Selective 3-phosphoinositide-dependent kinase 1 (PDK1) inhibitors: dissecting the function and pharmacology of PDK1.
    Medina JR
    J Med Chem; 2013 Apr; 56(7):2726-37. PubMed ID: 23448267
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 2-(3-Oxo-1,3-diphenylpropyl)malonic acids as potent allosteric ligands of the PIF pocket of phosphoinositide-dependent kinase-1: development and prodrug concept.
    Wilhelm A; Lopez-Garcia LA; Busschots K; Fröhner W; Maurer F; Boettcher S; Zhang H; Schulze JO; Biondi RM; Engel M
    J Med Chem; 2012 Nov; 55(22):9817-30. PubMed ID: 23106316
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Balancing potency, metabolic stability and permeability in pyrrolopyrimidine-based EGFR inhibitors.
    Han J; Henriksen S; Nørsett KG; Sundby E; Hoff BH
    Eur J Med Chem; 2016 Nov; 124():583-607. PubMed ID: 27614407
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases.
    Addie M; Ballard P; Buttar D; Crafter C; Currie G; Davies BR; Debreczeni J; Dry H; Dudley P; Greenwood R; Johnson PD; Kettle JG; Lane C; Lamont G; Leach A; Luke RW; Morris J; Ogilvie D; Page K; Pass M; Pearson S; Ruston L
    J Med Chem; 2013 Mar; 56(5):2059-73. PubMed ID: 23394218
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.
    Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S
    ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The synthesis and SAR of 2-amino-pyrrolo[2,3-d]pyrimidines: a new class of Aurora-A kinase inhibitors.
    Moriarty KJ; Koblish HK; Garrabrant T; Maisuria J; Khalil E; Ali F; Petrounia IP; Crysler CS; Maroney AC; Johnson DL; Galemmo RA
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5778-83. PubMed ID: 16949284
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthesis and biological evaluation of N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amines and their pyrido and pyrazino analogues as Ser/Thr kinase inhibitors.
    Loidreau Y; Marchand P; Dubouilh-Benard C; Nourrisson MR; Duflos M; Lozach O; Loaëc N; Meijer L; Besson T
    Eur J Med Chem; 2012 Dec; 58():171-83. PubMed ID: 23124214
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibiting NF-κB-inducing kinase (NIK): discovery, structure-based design, synthesis, structure-activity relationship, and co-crystal structures.
    Li K; McGee LR; Fisher B; Sudom A; Liu J; Rubenstein SM; Anwer MK; Cushing TD; Shin Y; Ayres M; Lee F; Eksterowicz J; Faulder P; Waszkowycz B; Plotnikova O; Farrelly E; Xiao SH; Chen G; Wang Z
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1238-44. PubMed ID: 23374866
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors.
    Lee W; Ortwine DF; Bergeron P; Lau K; Lin L; Malek S; Nonomiya J; Pei Z; Robarge KD; Schmidt S; Sideris S; Lyssikatos JP
    Bioorg Med Chem Lett; 2013 Sep; 23(18):5097-104. PubMed ID: 23932790
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis and SAR of novel 4-morpholinopyrrolopyrimidine derivatives as potent phosphatidylinositol 3-kinase inhibitors.
    Chen Z; Venkatesan AM; Dehnhardt CM; Ayral-Kaloustian S; Brooijmans N; Mallon R; Feldberg L; Hollander I; Lucas J; Yu K; Kong F; Mansour TS
    J Med Chem; 2010 Apr; 53(8):3169-82. PubMed ID: 20334367
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synthesis and evaluation of alkenyl indazoles as selective Aurora kinase inhibitors.
    Blanchard S; William AD; Lee AC; Poulsen A; Teo EL; Deng W; Tu N; Tan E; Goh KL; Ong WC; Ng CP; Goh KC; Bonday Z; Sun ET
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2443-7. PubMed ID: 20338758
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors.
    Tardy S; Orsato A; Mologni L; Bisson WH; Donadoni C; Gambacorti-Passerini C; Scapozza L; Gueyrard D; Goekjian PG
    Bioorg Med Chem; 2014 Feb; 22(4):1303-12. PubMed ID: 24468632
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 2-anilino-4-aryl-8H-purine derivatives as inhibitors of PDK1.
    Blanchard S; Soh CK; Lee CP; Poulsen A; Bonday Z; Goh KL; Goh KC; Goh MK; Pasha MK; Wang H; Williams M; Wood JM; Ethirajulu K; Dymock BW
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2880-4. PubMed ID: 22437109
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of new 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines as highly potent EGFR-TK inhibitors with Src-family activity.
    Kaspersen SJ; Han J; Nørsett KG; Rydså L; Kjøbli E; Bugge S; Bjørkøy G; Sundby E; Hoff BH
    Eur J Pharm Sci; 2014 Aug; 59():69-82. PubMed ID: 24769040
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Discovery of pyrazolopyrimidine derivatives as novel inhibitors of ataxia telangiectasia and rad3 related protein (ATR).
    Ramachandran SA; Jadhavar PS; Singh MP; Sharma A; Bagle GN; Quinn KP; Wong PY; Protter AA; Rai R; Pham SM; Lindquist JN
    Bioorg Med Chem Lett; 2017 Feb; 27(4):750-754. PubMed ID: 28131712
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 2-Anilino-4-(benzimidazol-2-yl)pyrimidines--a multikinase inhibitor scaffold with antiproliferative activity toward cancer cell lines.
    Determann R; Dreher J; Baumann K; Preu L; Jones PG; Totzke F; Schächtele C; Kubbutat MH; Kunick C
    Eur J Med Chem; 2012 Jul; 53():254-63. PubMed ID: 22560627
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthesis, SAR and biological evaluation of 1,6-disubstituted-1H-pyrazolo[3,4-d]pyrimidines as dual inhibitors of Aurora kinases and CDK1.
    Le Brazidec JY; Pasis A; Tam B; Boykin C; Black C; Wang D; Claassen G; Chong JH; Chao J; Fan J; Nguyen K; Silvian L; Ling L; Zhang L; Choi M; Teng M; Pathan N; Zhao S; Li T; Taveras A
    Bioorg Med Chem Lett; 2012 Mar; 22(5):2070-4. PubMed ID: 22326168
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Study of the PDK1/AKT signaling pathway using selective PDK1 inhibitors, HCS, and enhanced biochemical assays.
    Hofler A; Nichols T; Grant S; Lingardo L; Esposito EA; Gridley S; Murphy ST; Kath JC; Cronin CN; Kraus M; Alton G; Xie Z; Sutton S; Gehring M; Ermolieff J
    Anal Biochem; 2011 Jul; 414(2):179-86. PubMed ID: 21402045
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The phosphoinositide-dependent protein kinase 1 inhibitor, UCN-01, induces fragmentation: possible role of metalloproteinases.
    Alcántara-Hernández R; Hernández-Méndez A; García-Sáinz JA
    Eur J Pharmacol; 2014 Oct; 740():88-96. PubMed ID: 25016091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.